Key result
Lovastatin or fluvastatin reduced plasma LDL cholesterol by up to 37% and reduced platelet aggregation by 12-15% in hypercholesterolemic patients.
Why the study?
Does lovastatin or fluvastatin reduce plasma cholesterol and platelet aggregation in hypercholesterolemic patients?
Does lovastatin or fluvastatin reduce plasma cholesterol and platelet aggregation in hypercholesterolemic patients?
HMG-CoA reductase inhibitors (lovastatin and fluvastatin) reduce LDL cholesterol, platelet aggregation, and LDL oxidation, contributing to their antiatherogenic effects.
Answers are grounded in this paper and cite their sources.
May support pleiotropic antiplatelet effects of these statins; leaves open whether benefits extend to clinical outcomes in randomized trials.
To assess the effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on plasma cholesterol concentrations and on platelet aggregation, lovastatin or fluvastatin, 40 mg daily, was given to hypercholesterolemic patients. After 24 weeks, plasma low-density lipoprotein (LDL) cholesterol concentrations were reduced by 37% after lovastatin therapy and 29% after fluvastatin therapy. The platelet cholesterol/phospholipid ratio was reduced by 33% and 26%, respectively. Platelet aggregation was significantly reduced by 12-15% (p < 0.01) after 4 weeks of therapy with either agent. Lovastatin or fluvastatin therapy reduced platelet aggregation through an in vivo hypocholesterolemic action on the platelet cholesterol content and also through a direct effect on platelet function, as a result of drug binding to the platelets. We also studied the effect of these HMG-CoA reductase inhibitors on LDL susceptibility to oxidation. LDL oxidation (induced by copper ions) was reduced by 31% after lovastatin therapy and by 37% after fluvastatin therapy. The inhibitory effect of HMG-CoA reductase inhibitors on LDL oxidation involved their stimulatory effect on the removal of LDL from the circulation and a direct binding effect of the drugs to the lipoprotein. Because HMG-CoA reductase inhibitors can inhibit platelet aggregation, macrophage foam cell formation, and LDL oxidation, major contributors to atherogenesis, the use of these drugs can significantly attenuate the atherosclerotic process.
No takes yet. Share an insight, caveat, or question.
Aviram et al. (1998) studied Hypercholesterolemia. Lovastatin or fluvastatin was evaluated on Plasma low-density lipoprotein (LDL) cholesterol concentrations and platelet aggregation (37% and 29% reduction in LDL; 12-15% reduction in platelet aggregation, p=< 0.01). Lovastatin or fluvastatin reduced plasma LDL cholesterol by up to 37% and reduced platelet aggregation by 12-15% in hypercholesterolemic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: